Discovery of first-in-class precision antibody drug conjugates with a potent SMARCA2/4 dual degrader payload that safely achieve maximal and tumor specific degradation and efficacy in mouse models

Carter J, Agarwal A, Sivakumar M, Reichelderfer A, Park J, Osinubi O, Holmes R, Fultang N, Schwab A, Rager J, Stahl N, Cote J, Crossan A, Chen C, Pawley S, Wang M, Geeganage S, Lee S, Combs A, Scherle P, Buesking A and Ito K